EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Additional B‐Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real‐World Retrospective Observational Single‐Center Cohort Study

Jingjing Jin, Meng Tan, Minghui Zhao, Ying Tan

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.71113 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift MedComm, online erschienen am 29.10.2026. Verfasst von Jingjing Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division Department of Medicine Institute of Nephrology Key Laboratory of Renal Disease Key Laboratory of Chronic Kidney Disease Prevention and…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoid (GC) withdrawal remains a major challenge for lupus nephritis (LN). In this 20‐year retrospective cohort, we evaluated whether B‐lymphocyte stimulator (BLyS) inhibitors facilitated GC discontinuation. Among 702 LN patients, 553 were treated with standard‐of‐care alone, and 149 received add‐on BLyS inhibitors (belimumab or telitacicept). Patients receiving BLyS inhibitors achieved a higher rate of GC withdrawal than those receiving standard‐of‐care alone (10.7% vs. 5.61%, p = 0.026). Kaplan–Meier analysis confirmed a higher cumulative incidence of GC withdrawal in the BLyS inhibitor group ( p = 0.001). After adjusting for age, sex, Systemic Lupus Erythematosus Disease Activity Index, acute kidney injury, nephrotic syndrome, and renal histopathology, time‐dependent Cox regression revealed that BLyS inhibitor therapy was independently associated with a higher GC withdrawal rate (hazard ratio [HR] = 7.97, 95% confidence interval [CI]: 4.11–15.5, p < 0.001). Exploratory subgroup analyses indicated that among GC‑discontinued patients, Class IV LN predominated in the BLyS inhibitor group, whereas Class V LN was more prevalent in controls. During follow‐up, no renal flares occurred in BLyS inhibitor‐treated patients who discontinued GCs, though there was no significant between‐group difference. In conclusion, add‐on BLyS inhibitor therapy may serve as a potential steroid withdrawal‐permissive approach for LN, pending further prospective validation of its clinical applicability.

Schlagwörter

Stichwörter der Autor:innen

B‐lymphocytestimulator inhibitorsbelimumabglucocorticoids withdrawallupus nephritistelitacicept

Autor:innen und Institutionen

  • Renal Division Department of Medicine Institute of Nephrology Key Laboratory of Renal Disease Key Laboratory of Chronic Kidney Disease Prevention and Treatment Peking University First Hospital, Peking University Beijing…
  • Ministry of Health of China, Ministry of Education of China, Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences Beijing China.
  • Departments of Nephrology Hebei Key Laboratory of Vascular Calcification in Kidney Disease The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei China.
  • Hebei Clinical Research Center for Chronic Kidney Disease Shijiazhuang Hebei China.
  • Department of Nephrology Peking University First Hospital Taiyuan Branch (Taiyuan Central Hospital of Shanxi Medical University) Taiyuan China.

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Key Research and Development Program of China

Zitieren

APA

Jin, J., Tan, M., Zhao, M., & Tan, Y. (2026). Additional B‐Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real‐World Retrospective Observational Single‐Center Cohort Study. MedComm, 7(11). https://doi.org/10.1002/mco2.71113

Vancouver

Jin J, Tan M, Zhao M, Tan Y. Additional B‐Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real‐World Retrospective Observational Single‐Center Cohort Study. MedComm. 2026;7(11). doi:10.1002/mco2.71113

BibTeX
@article{Jin2026,
  author = {Jin, Jingjing and Tan, Meng and Zhao, Minghui and Tan, Ying},
  title = {Additional B‐Lymphocyte Stimulator Inhibitors Treatment Facilitated Glucocorticoid Withdrawal in Lupus Nephritis Patients: A Real‐World Retrospective Observational Single‐Center Cohort Study},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {11},
  doi = {10.1002/mco2.71113}
}
Kostenlos starten →